Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation‐induced antigens (CD25 and CD69)

T lymphocytes play an important role in allogeneic bone marrow/stem cell transplantation by supporting engraftment and immune recovery. Moreover, donor T cells have been shown to mediate the so‐called graft‐versus‐leukaemia effect and are, therefore, increasingly used for adoptive immunotherapy. However, T‐cell infusions are associated with the risk of a graft‐versus‐host reaction, which may lead to a life‐threatening disease. To overcome this problem, we followed a new strategy for the exclusive depletion of alloreactive cells. We activated allogeneic T cells by cultivation on an adherent cell layer derived from peripheral blood. We then depleted activated cells based on the expression of CD25, CD69 or both activation‐induced antigens using magnetic cell sorting. Mixed lymphocyte culture (MLC) reactions and helper T‐lymphocyte precursor cell frequency (HTLP‐f) assays demonstrated that this technique led to a significant decrease in alloreactivity of ‘donor’ cells, which at the same time preserved reactivity against third‐party cells. The lowest level of alloreactivity was found when CD25 and CD69 antibodies were used together for depletion. This corresponds with our observation that expression of CD25 or CD69 may partially represent different activation pathways. We conclude that ex vivo depletion of CD25‐ and CD69‐expressing alloreactive cells may help to overcome limitations of adoptive immunotherapy.

[1]  A. Zander,et al.  Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements , 1999, Gene Therapy.

[2]  H. Prentice,et al.  Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis , 1999, Bone Marrow Transplantation.

[3]  J. Román,et al.  Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft , 1999, Bone Marrow Transplantation.

[4]  F. Marini,et al.  Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. , 1999, Transplantation.

[5]  Raptis,et al.  Specific depletion of alloreactive T cells in HLA‐identical siblings: a method for separating graft‐versus‐host and graft‐versus‐leukaemia reactions , 1998, British journal of haematology.

[6]  H. Prentice,et al.  Temporal dynamics of CD69 expression on lymphoid cells. , 1997, Journal of immunological methods.

[7]  A. Zander,et al.  Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. , 1997, Human gene therapy.

[8]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[9]  P. Ricciardi-Castagnoli,et al.  Dendritic cells hold promise for immunotherapy. , 1997, Immunology today.

[10]  A. Balsari,et al.  Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. , 1997, Cytometry.

[11]  J. Hurwitz,et al.  Eliminating graft-versus-host potential from T cell immunotherapeutic populations. , 1996, Bone marrow transplantation.

[12]  A. Barrett,et al.  GRAFT‐VERSUS‐LEUKAEMIA: UNDERSTANDING AND USING THE ALLOIMMUNE RESPONSE TO TREAT HAEMATOLOGICAL MALIGNANCIES , 1996, British journal of haematology.

[13]  I. Pastan,et al.  Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. , 1996, Bone marrow transplantation.

[14]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[15]  A. Barrett,et al.  Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. , 1994, Bone marrow transplantation.

[16]  Craig W. Reynolds,et al.  Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? , 1994, Blood.

[17]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[18]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[19]  H. Lother,et al.  Homodimeric murine interleukin-3 agonists indicate that ligand dimerization is important for high-affinity receptor complex formation. , 1994, Growth factors.

[20]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[21]  A. Freedman,et al.  Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. , 1992, Journal of Clinical Oncology.

[22]  R. Macklis,et al.  Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. , 1991, Blood.

[23]  R. Truitt,et al.  Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. , 1991, Bone marrow transplantation.

[24]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[25]  S. Feig,et al.  Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[26]  A. Fischer,et al.  SPECIFIC ELIMINATION OF ALLOREACTIVE T CELLS BY AN ANTI‐INTERLEUKIN-2 RECEPTOR B CHAIN‐SPECIFIC IMMUNOTOXIN , 1990, Transplantation.

[27]  J. Wagner,et al.  Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. , 1990, Blood.

[28]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[29]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[30]  K. Sullivan,et al.  Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.

[31]  R. Good,et al.  TRANSPLANTATION FOR ACUTE LEUKAEMIA WITH HLA-A AND B NONIDENTICAL PARENTAL MARROW CELLS FRACTIONATED WITH SOYBEAN AGGLUTININ AND SHEEP RED BLOOD CELLS , 1981, The Lancet.